Clinical Research Directory

Inclusion Criteria: * Signed Written Informed Consent * Study participants must have signed and dated an IEC approved written informed consent form in accordance with regulatory and institutional guidelines. * Study participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. * Histologically confirmed, resectable adenocarcinoma of the esophagus (uT2, uN+, cM0 or uT3, cNx, cM0), with the following specifications: * Medical and technical operability * No preceding cytotoxic or targeted therapy * No prior partial or complete tumor resection * Male or female patients \> 18 years of age at time of study entry * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life expectancy of at least 12 months * Adequate normal organ function as defined below. Screening laboratory values must meet the following criteria and should be obtained within 28 days prior to registration * WBC ≥ 1500/μL * Neutrophils ≥ 1000/μL * Platelets ≥ 75 x103/μL * Hemoglobin \> 9.0 g/dL * Serum creatinine ≤ 1.5 x institutional ULN or calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault) * AST/ALT ≤ 2,5 x institutional ULN * Total Bilirubin ≤ 1.5 x institutional ULN * Body weight \> 30kg * Reproductive Status * Women of childbearing potential must have a negative serum or urine pregnancy test within one until two weeks prior to the start of neoadjuvant treatment and after surgery before starting adjuvant treatment. * Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago. * Women must not be breastfeeding. * Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Exclusion Criteria: * Study participants with squamous cell carcinoma of the esophagus * Prior treatment with chemotherapy, targeted therapy or radiotherapy for treatment of advanced cancer disease less than 5 years. * Enrollment is possible for patients with: * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a study participant's ability to comply with the study requirements, substantially increase risk to the study participant, or impact the interpretability or study results * Active or prior documented autoimmune or inflammatory disorders. The following are exceptions to this criterion: * Patients with vitiligo or alopecia * Patients with hypothyroidism stable on hormone replacement * Any chronic skin condition that does not require systemic therapy * Patients with celiac disease controlled by diet alone. * Inhaled or topical steroids and adrenal replacement steroid doses \>10mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. * History of active primary immunodeficiency * History of any allogenic organ transplantation with currently intake of immune suppressive treatment * Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity. FEV 1 \< 75% * Patients has known current symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. ∙ * Prisoners or study participants who are involuntarily incarcerated Pregnancy or breastfeeding females ∙ Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.